Entera Bio (NASDAQ:ENTX) Earns Outperform Rating from Analysts at Leerink Partners

Analysts at Leerink Partners started coverage on shares of Entera Bio (NASDAQ:ENTX) in a note issued to investors on Friday, Briefing.com reports. The brokerage set an “outperform” rating and a $9.00 price target on the stock. Leerink Partners’ price objective would indicate a potential upside of 197.03% from the company’s current price.

Several other equities research analysts have also recently commented on ENTX. HC Wainwright reissued a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a report on Friday, July 17th. Finally, Wall Street Zen raised Entera Bio to a “sell” rating in a research report on Saturday, August 8th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $9.00.

Entera Bio Stock Up 2.4%

Shares of ENTX stock opened at $3.03 on Friday. Entera Bio has a 12-month low of $0.91 and a 12-month high of $4.20. The firm has a fifty day moving average of $2.77 and a 200-day moving average of $1.81. The firm has a market capitalization of $526.70 million, a price-to-earnings ratio of -8.66 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX) last announced its earnings results on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06).

Institutional Trading of Entera Bio

An institutional investor recently raised its position in Entera Bio stock. Renaissance Technologies LLC grew its holdings in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 338.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 473,442 shares of the company’s stock after acquiring an additional 365,441 shares during the quarter. Renaissance Technologies LLC owned 0.96% of Entera Bio worth $526,000 at the end of the most recent quarter. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

About Entera Bio

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.